In this context, the success of this combination therapy suggests both inhibition of the BRAF fusion protein by sorafenib and of the downstream mTOR pathway by temsirolimus synergizes, although the specific mechanism of tumor regression awaits further investigation. Here, BRAF is linked to neoplasm.